| 摘要: |
| 目的 运用成本-效果分析评价化疗(依托泊苷联合卡铂/顺铂)、化疗联合PD-L1(阿替利珠单抗/度伐利尤单抗)和化疗联合PD-1(斯鲁利单抗)三种方案治疗小细胞肺癌的经济性。方法 回顾性分析山东省立医院2020年1月~2023年4月收治的94例小细胞肺癌患者的病历资料,根据不同治疗方案分为三组,评估三组患者治疗四周期后的临床疗效,记录不良反应,并进行成本-效果分析。结果 三组客观缓解率分别为:化疗组56.25%,化疗联合PD-L1组63.33%,化疗联合PD-1组62.50%,差异无统计学意义(P>0.05)。三组之间白细胞减少、血小板减少、肝功异常不良反应发生情况无显著差异(P>0.05),胃肠道不良反应发生率分别为:化疗组41.66%,化疗联合PD-L1组40.00%,化疗联合PD-1组6.25%,差异有统计学意义(P<0.05)。以客观缓解率为临床疗效指标,三组治疗方案的成本-效果比分别为480.88、2 026.80和1 001.47;以化疗组为参照,化疗联合PD-L1组和化疗联合PD-1组的增量成本-效果比分别是14 309.06和5 686.81。敏感度分析与成本-效果分析的结论一致。结论 广泛期小细胞肺癌的一线治疗中,单独化疗与联合免疫方案相比,ORR相似,化疗组的成本-效果比最优。 |
| 关键词: 小细胞肺癌 化疗 程序性细胞死亡受体配体1 程序性细胞死亡受体1 成本-效果分析 |
| DOI:10.13506/j.cnki.jpr.2024.03.014 |
| 基金项目:山东省医学会临床科研资金—齐鲁专项多中心临床研究项目(No.YXH2022DZX02006) |
|
出版日期:2024-03-25
|
|
| Cost-effectiveness analysis of chemotherapy and chemotherapy combined with immunotherapy in the treatment of small cell lung cancer |
| PEI Yihan1,WANG Shuping1,2,ZHANG Jindi1,BI Yunyan1,ZHANG Wen1 |
| (1.Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong Jinan 250021, China;2.Laiwu People's Hospital of Jinan,Jinan 271100, China) |
| Abstract: |
| Objective Cost-effectiveness analysis was used to evaluate the economics of three regimens in the treatment of small cell lung cancer : chemotherapy (etoposide combined with carboplatin/cisplatin), chemotherapy combined with PD-L1 (atezolizumab/durvalumab) and chemotherapy combined with PD-1 (Serplulimab).Methods The medical records of 94 patients with small cell lung cancer admitted to Shandong Provincial Hospital from January 2 020 to April 2 023 were retrospectively analyzed and divided into three groups according to the treatment regimen. The clinical efficacy of the three groups after four cycles of treatment was evaluated, adverse effects were recorded, and cost-effectiveness analysis was performed.Results The objective response rates of the three groups were : chemotherapy group 56.25%, chemotherapy combined with PD-L1 group 63.33%, chemotherapy combined with PD-1 group 62.50%, the difference was not statistically significant(P>0.05). There was no significant difference in the incidence of leukopenia, thrombocytopenia and abnormal liver function among the three groups (P>0.05), and the incidence of gastrointestinal adverse reactions was 41.66 % in the chemotherapy group, 40.00 % in the chemotherapy combined with PD-L1 group, and 6.25 % in the chemotherapy combined with PD-1 group, the difference was statistically significant (P<0.05). The objective response rate was used as the clinical efficacy index, and the cost-effectiveness ratios of the three groups were 480.88,2 026.80 and 1 001.47, respectively. The incremental cost-effectiveness ratios of chemotherapy combined with PD-L1 group and chemotherapy combined with PD-1 group were 14 309.06 and 5 686.81, respectively. The conclusion of sensitivity analysis is consistent with that of cost-effectiveness analysis. Conclusion In the first-line treatment of extensive-stage small cell lung cancer, the ORR of chemotherapy alone was similar to that of combined immunization regimen, and the cost-effectiveness ratio of chemotherapy group was the best. |
| Key words: Small cell lung cancer Chemotherapy programmed cell death-1 Programmed death-ligand 1 Cost-effectiveness analysis |